Risperidone and ethyl pyruvate have protective effects against ketamine-induced cognitive impairments in mice

Basit Öğe Kaydı
dc.contributor.authorKelle, İlker
dc.contributor.authorEriman, H.
dc.contributor.authorErdi̇nç, Meral Alper
dc.contributor.authorUyar, Emre
dc.date.accessioned2023-03-22T06:37:07Z
dc.date.available2023-03-22T06:37:07Z
dc.date.issued2022en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Tıbbi Farmakoloji Ana Bilim Dalıen_US
dc.description.abstractOBJECTIVE: Ketamine, an N-methyl D-aspartic acid receptor antagonist drug, is reported to produce memory disruptions. The aim of this study was to investigate the protective effects of ethyl pyruvate (EP), a pyruvic acid derivative, and risperidone, an atypical anti-psychotic drug, against ketamine-induced cognitive disturbances. MATERIALS AND METHODS: A passive-avoidance test, a novel object recognition test, and a modified elevated plus maze test were used to assess memory functions. Hippocampal malondialdehyde (MDA) levels were measured to determine the oxidation levels. RESULTS: Ketamine applications produced memory deficits in all tests and insignificantly increased MDA levels, which were alleviated by risperidone, EP, and combination treatments. CONCLUSIONS: Increased oxidative stress and neurotransmission imbalance can be responsible for ketamine-induced memory disruptions. With its antioxidant effects, EP may be helpful to reduce cognitive impairments related to schizophrenia either alone or in combination with antipsychotics.en_US
dc.identifier.citationKelle, İ., Eriman, H., Erdinc, M. ve Uyar, E. (2022). Risperidone and ethyl pyruvate have protective effects against ketamine-induced cognitive impairments in mice. European Review for Medical and Pharmacological Sciences, 26(5), 1708-1716.en_US
dc.identifier.endpage1716en_US
dc.identifier.issn1128-3602
dc.identifier.issue5en_US
dc.identifier.pmid35302220
dc.identifier.scopusScopusIdYok
dc.identifier.scopusqualityQ2
dc.identifier.startpage1708en_US
dc.identifier.urihttps://hdl.handle.net/11468/11478
dc.identifier.volume26en_US
dc.identifier.wosWOS:000771549500037
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKelle, İ.
dc.institutionauthorEriman, H.
dc.institutionauthorErdinç, M.
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review for Medical and Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEthyl pyruvateen_US
dc.subjectRisperidoneen_US
dc.subjectKetamineen_US
dc.subjectSchizophreniaen_US
dc.subjectCognitive symptomsen_US
dc.titleRisperidone and ethyl pyruvate have protective effects against ketamine-induced cognitive impairments in miceen_US
dc.titleRisperidone and ethyl pyruvate have protective effects against ketamine-induced cognitive impairments in mice
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu